Novo Nordisk’s Wegovy pill shattered sales forecasts in its first two weeks, rocketing the company’s stock 7% higher and igniting a frenzy for the first oral weight-loss blockbuster.
Story Highlights
- Wegovy pill launched January 5, 2026, racking up over 18,000 prescriptions in week one and 26,100 in week two—totaling 44,100.
- Week two sales exceeded Novo’s 2026 target pace by 1,200%, per Bank of America analysts who projected just 2,000 weekly prescriptions needed.
- The launch triggered an immediate 7% stock surge, validating the potential of oral GLP-1s to capture 25% of a $95 billion market by 2030.
- Outpaced Eli Lilly’s Zepbound, which hit only 25,000 prescriptions after a full month in late 2023.
Wegovy Pill Launch Triggers Prescription Avalanche
Novo Nordisk released the Wegovy pill on January 5, 2026, marking the debut of the first oral GLP-1 drug approved for weight loss. IQVIA data captured over 18,000 prescriptions from January 5 to 12.
Demand accelerated sharply the next week, with 26,100 prescriptions from January 12 to 19. This two-week total of more than 44,000 prescriptions dwarfed initial expectations and signaled a seismic shift from injectable dominance.
Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance https://t.co/qMopInI5w6
— CNBC International (@CNBCi) May 6, 2026
Sales Velocity Crushes Analyst Projections
Bank of America analysts determined Novo needed roughly 2,000 weekly prescriptions to meet its 2026 sales goals for the pill. Week two’s 26,100 prescriptions obliterated that benchmark by 1,200%.
This explosive uptake reflects pent-up consumer demand for a convenient pill alternative to weekly injections like the original Wegovy or Eli Lilly’s Zepbound. Common side effects—nausea, diarrhea, dizziness, vomiting—did not deter early adopters amid the obesity crisis gripping America.
Stock Surge Validates Market Disruption
Novo Nordisk’s shares jumped 7% immediately after the sales data emerged, rewarding investors who bet on oral GLP-1 innovation. Goldman Sachs projects oral versions capturing 25% of the GLP-1 market, forecasted to reach $95 billion by 2030.
This launch disrupts injectables, which previously ruled due to efficacy in slashing stroke and heart attack risks tied to obesity. Novo’s Danish roots in diabetes treatments positioned it perfectly for this weight-loss pivot.
Historical Sales Context Highlights Superior Launch
Eli Lilly’s Zepbound injectable managed just 25,000 prescriptions after one full month post-launch in late 2023. Wegovy’s pill achieved more than that in half the time, underscoring superior velocity.
Quarterly Wegovy sales data shows explosive growth; Q4 2024 hit a record 20 billion Danish kronor. The pill’s convenience—swallow daily versus inject weekly—drives adoption, promising broader access for the 40% of American adults battling obesity.
Conservatives applaud market-driven solutions like this, empowering personal responsibility over government mandates.
Facts confirm the pill’s rapid success aligns with free-market innovation, delivering real health tools without bureaucratic interference. Future quarters will test if this momentum sustains amid competition.
$GDRX Wegovy pill sales smash forecasts, sending Novo Nordisk stock 7% higher
— Shivaprakash Kallasarpe (@kallasarpe21271) May 6, 2026
Sources:
First GLP-1 weight loss pill sales surge, giving Novo a market bump
Novo Nordisk: Wegovy sales by quarter 2025 – Statista
